DAY 1
Wednesday, June 25th 2025
8h00
Registration and welcome coffee
8h40
Welcome Address
- Descartes Auditorium
8h50
OPENING KEYNOTE LECTURES
- Descartes Auditorium
8h50
Radioconjugates: Bridging Innovation with Industrial Feasibility
Elsa Kress
Head of Business Development
MabDesign, France
9h00
Advances in Multispecific Antibody Development
Paul W.H.I Parren
Board Chair
The Antibody Society, USA
Chief Scientific Officer
Gyes BV, Netherlands
Professor
Leiden University Medical Center, Netherlands
9h30
Biomarkers of response and resistance to ADCs across solid tumors
Barbara Pistilli
MD, Chair of the Breast Cancer Unit
Gustave Roussy , France
10h00
Coffee Break at Exhibition Hall
10h30
Discovery and optimization of Ms/Bs Abs, ADCs, Immunocytokines, and Next-Gen anti-PD-1
- Descartes Auditorium
10h30
Bispecific antibodies engaging the adaptive and innate immune systems via CD28 and CD47 targeting
Walter Ferlin
CSO
Light Chain Bioscience, Switzerland
11h00
Lusvertikimab, a first-in-class IL7 receptor antagonist, in moderate to severe ulcerative colitis: results of a multicenter, randomized, placebo-controlled phase II study (CoTikiS)
Silvia Comis
Chief Clinical and Medical Research Officer
OSE Immunotherapeutics, France
11h30
Boosting CD3-Targeting Bispecific Antibodies: Exploring Synergistic Combination Partners
Abdullah Elsayed
Group Leader
Philochem AG, Switzerland/ Italy
12h00
Accelerating Drug Discovery Using AI-Enhanced Advanced Antibody Development Platforms
Yu-Chih Lin
Technical specialist
Sino Biological, Germany
Antibody development against challenging targets such as GPCR, channels, etc
- Pasteur Room
10h30
Targeting gonadotropin receptors with single domain antibodies to control reproduction and treat associated dysfunctions
Eric Reiter
DR1, PhD, Deputy director of UMR PRC, BIOS team
MUSCA team (INRIA/INRAE/CNRS), INRAE Centre Val de Loire, Nouzilly, France
11h00
A first in class anti-Follicle Stimulating Hormone potentiating therapeutic antibody as a breakthrough treatment for fertility
Elodie Kara
R&D Project Manager
IGYXOS, France
11h30
Tiny but Mighty ! Single domain antibodies for cancer imaging and immunotherapies
Patrick Chames
Team Leader Antibody Therapeutics and Immunotargeting
Marseille Cancer Research Center, France
12h00
SPR-Based Platform for the Selection and Characterization of Therapeutic Monoclonal Antibodies Targeting Amyloid Aggregates
Claude Nogues
CSO & Co-founder
Kimialys, France
12h10
Lunch at Exhibition Hall
13h00
Workshop :Bridging Innovation to the Clinic: Smart First-in-Human Dose Selection for Novel Targeted Therapeutics
- PASTEUR ROOM
Lionel Renaud
PK/PD and Systems Pharmacology Modeler
LYO-X, Switzerland
Saeed Masroor
Scientist in Quantitative Systems Pharmacology
LYO-X, Switzerland
14h00
Discovery and optimization of Ms/Bs Abs, ADCs, Immunocytokines, and Next-Gen anti-PD-1
- Descartes Auditorium
14h00
TUB-040, a Napi2b-targeting ADC currently tested in clinical trials, shows long-lasting anti-tumor efficacy via Topoisomerase-I inhibition and excellent tolerability
Björn Hock
Chief Development Officer
Tubulis, Germany
14h30
INA03: A potent transferrin-competitive ADC against CD71 for safer Acute Leukemia treatment. How to transform a undruggable to a druggable target
Pierre Launay
CSO
Inatherys, France
15h00
Enhancing Mab and BsAb Discovery: From Strategic Design to Fit-for-Purpose Screening and Characterization
Winfried Elis
Senior BD Manager
Wuxi Biologics CRO Services, Germany
15h15
The role of developability as part of successful bioconjugate lead candidate selection
Rob Holgate
Vice-President, Research and Innovation
ABZENA, UK
Challenges and opportunities in alternative delivery approaches
- Pasteur Room
14h00
A multidisciplinary perspective on subcutaneous biologics delivery
Sylvain Huille
BioPharmaceutics Development France
SANOFI, France
14h30
Topical Application of Nebulized Polyclonal IgG: from Proof of Concept into Clinical Development
Anna Schnell
Senior Scientist
CSL Behring, Switzerland
15h00
VHH to treat brain disorders and how they can go through the BBB
Philippe Rondard
Team Leader, Neuroreceptors: Dynamics and Functions
Institut de Génomique Fonctionnelle, France
15h30
From Delivery to Detection: Nanocarrier and Antibody Synergy in Advanced Therapy Development
Foka Venema
Senior Scientist Project Manager
ARDENA, Netherlands
15h40
Coffee Break at Exhibition Hall
16h00
Pitch Session : Innovative Approaches and New trend Technologies
- Descartes Auditorium
Call for Abstracts - Deadline April 4th 2025 !
16h00
Patient-Derived lymphoma Spheroids as preclinical models for predicting patient responses to advanced therapies in B-NHL: example of glofitamab in follicular lymphoma
Christine Bezombes
Research investigator
Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
16h10
Development of pH-Modulated Antibodies, that Recognize Immune System Checkpoints
Diego Barba
Medical Doctor
Montpellier Cancer Research Institute (IRCM), France
16h20
High-Sensitivity MAPPs for High-Confidence Immunogenicity Risk Assessment in Therapeutic Antibody Development
Elise Pepermans
CEO & Co-founder
ImmuneSpec, Belgium
16h30
A Sustainable Droplet Microfluidic Platform for Fast Cross-Species Functional Antibody Discovery from Minimal Samples
François Côte
Business Developer
CER Groupe, Belgium
16h40
Unlocking the Potential of Bispecific T-Cell Engagers: Pioneering HER3-Targeted Therapies for Cancer Treatment
Giuseppe Roscilli
Chief Technology Officer and Dept Director
Takis Biotech, Italy
16h50
First-in-class anti-TRPV6 antibody as a new therapeutic agent in cancer
Johanna Marines
Head of Preclinical Development
Mabqi, France
17h00
Smaller ADC formats based on Therano-Stick ™ technology could make the difference for solid tumors!
Meddy El Alaoui
CEO
AbTx, France
17h10
Microalgae-produced antibody as effective as those produced in mammalian cells
Muriel Bardor
CEO & CSO
Alga Biologics, France
17h20
Unveiling the Pan-Cancer potential of dual-mechanistic uPAR-targeting ADCs across cancers
Virginia Metrangolo
Researcher
The Finsen Laboratory, Rigshospitalet, Denmark
Effector cell redirection (heme/solid)
- Pasteur Room
16h00
Harnessing NK cells for the treatment of cancer: update on NKp46 engagers
Olivier Demaria
R&D Director
Innate Pharma, France
16h30
Developability Screening Cascade to Advance Multispecific Therapeutic Antibodies to the Clinic
Cyrille Dreyfus
Associate Director
Ichnos Glenmark Innovation, Switzerland
17h00
MAIT engagers: Providing an effective therapeutic window to treat solid tumors
Julie Prigent
Associate Director, R&D
Biomunex Pharmaceuticals, France
17h30
Poster Presentation Session - Announcement of "BEST POSTER" Prize
- Exhibition Hall
Pitch in front of Investors - Private session
- Pasteur Room
19h00
Dinner Cocktail Reception at Exhibition Hall
21h00
End of DAY 1
DAY 2
Thursday, June 26th 2025
8h00
Welcome coffee
8h20
Fc domains of mAbs, ADCs, and BsAbs : Potency, Safety, Regulatory & IP
- Descartes Auditorium
Session Sponsored by
8h20
Fc-mediated functions modulation of mAbs, ADCs, BsAbs and Fc-fusion proteins
Alain Beck
Senior Director, Biologics CMC & developability
Pierre Fabre , France
8h50
Still living in LALA land? Are there better ways to eliminate unwanted Fc effector functions?
Geoff Hale
CEO
mAbsolve, UK
9h15
Studying structure/function relation of therapeutic antibodies using LC and MS
Koen Sandra
CEO
RIC Group, Belgium
9h40
The confusing patent landscape regarding Fc domain domain engineering: ADCC, serum half life and more
Ulrich Storz
Senior Partner - Patent Attorney
Michalski Huettermann, Germany
Biomarkers development for next-generation Antibodies treatments
- Pasteur Room
8h20
Clinical and molecular biomarkers for optimization cohorts in early-phase oncology trials
Elisa Fontana
MD, PhD, Hospital Medical Director
Sarah Cannon Research Institute in London, UK
8h50
Molecular imaging to get insight into (modified) antibody behavior in patients
Derk Jan de Groot
MD, PhD, Medical Oncologist
UMCG Universitair Medisch Centrum Groningen, The Netherlands
9h20
Navigating In-vitro Diagnostics Regulation (IVDR) frameworks in early drug development
Rafael Grochot
MD, MSc, Medical Oncologist
Sarah Cannon Research Institute in London, UK
9h50
Writing the Future of Biologics with an Integrated Offering of Immunization, Libraries, and Machine Learning
Leonie Alten
Staff, Scientific Development Scientists, SynBio
Twist Bioscience, USA
10h00
Coffee Break at Exhibition Hall
10h30
Non-conventional ADCs
- Descartes Auditorium
10h30
Enhancing therapeutic index of antibody-drug conjugates through site-specific DAR1 conjugation
Fabian Schlimpen
Senior Scientist
Syndivia, France
11h00
Antibody-Vincristine Conjugates as Potent Anticancer Therapeutic Agents
Héloïse Cahuzac
Postdoctoral Researcher
BioFunctional Chemistry Team, University of Strasbourg, France
11h30
Antibody Fragment Drug Conjugates: Next-Generation ADCs Tailored for Solid Tumours
Mahendra Deonarain
CEO
Antikor Biopharma Ltd, UK
12h00
ADC Affinity and Tissue Penetration: Tools for Comprehensive Characterization
Stéphane Pinhal
Technical Sales Manager
Bruker Biosensors, Germany
Mechanisms of resistance to ADCs, ADA, and biomarker-driven versus payload resistance
- Pasteur Room
10h30
Novel Multi-Payload ADCs Assembled in One Step from Native Antibodies that Show Excellent Biophysical Properties and High Efficacy in vivo
Philipp Spycher
Founder and CSO
Araris Biotech AG, Switzerland
11h00
Antibody Conjugates in Oncology and Beyond
Christian Kunz
Vice President Biologics Discovery
Ridgeline Discovery, Switzerland
11h30
From Single Cell to Stable Clone: Optimizing Cell Line Development for Biotherapeutics
Ludivine Aubignat
Reagent Sales Specialist EMEA
Advanced Instruments – Solentim, France
12h00
A comprehensive discovery and engineering workflow for developing innovative anti-Nectin-4 antibody drug conjugates
Jacques Fieschi
CSO
MImAbs, France
12h10
Lunch at Exhibition Hall
13h00
Round Table "Comment évoluer grâce aux dispositifs de financement Nationaux et Européens "
- Pasteur Auditorium
Marie-Christine Maurel
Chief Scientific Officer & Founder
IGYXOS Biotherapeutics, France
Sylvain Yon
Chief Executive Officer
Mabqi, France
Julie Lellouche
Responsable Sectorielle Santé
Bpifrance, France
Roxane Brachet
National Contact Point Health
Ministère de l'Enseignement
supérieur et de la Recherche
Pierre d'Epenoux
Chief Executive Officer
ImCheck Therapeutics, France
Guirec Cloarec
Innovation Project Manager
Mabdesign, France
14h00
AI-based Computational Approaches for Antibody Discovery & Optimization & Accelerate Clinical Trials
- Descartes Auditorium
14h00
In silico antibody discovery: rethinking the funnel-shape process
Astrid Musnier
Co-founder & Head of Biology
MAbSilico, France
14h30
Revolutionizing immuno-oncology drug target discovery, through AI/ML predictive computational discovery platform Unigen
Zoya Alteber
Director Research and drug Discovery
Compugen Ltd, Israel
15h00
Powering explainable AI to optimize biological prescriptions and drug development in IBD using real-world data
Fréderic Parmentier
VP of Data Science
Ariana Pharma, France
15h30
Transforming Antibody Therapeutics: The Role of AI in Development and Engineering
Robert Ford
Field Application Scientist (FAS)
GenScript Biotech, Netherlands
Emerging 3D preclinical models
- Pasteur Room
14h00
Patient-Derived tumour Explants as a preclinical model system for predicting patient responses to advanced therapies
Catrin Pritchard
Professor of Cancer Biochemistry
Leicester Cancer Research Centre, University of Leicester, UK
14h30
Hydrogel droplet microfluidic approach for high-throughput drug screening in spheroids
Guillaume Mottet
Senior Director of Biologics Discovery
Microfluidics Team, SANOFI, France
15h00
In Vivo New Alternative Methods (NAMs) for Drug Evaluation: From Cancer Cell Line 3D Models to Patient Tumor Avatars
Jean Viallet
CEO
INOVOTION, France
15h40
Closing Keynote
- Descartes Auditorium
15h40
The Rise of T Cell Engaging Antibodies
Patrick A. Baeuerle
Co-Founder, Chief Scientific Advisor and Chairman of the SAB
Cullinan Therapeutics Inc., USA
Honorary Professor of Immunology
Institute for Immunology, Ludwig Maximilian University, Germany
16h10
Announcement of AIS2026
16h30
